EUVIMEDOpdag EUVIMED
ÜbersichtsarbeitOpen access · CC BY 4.0

Engineering Antibody Evolution: Germline‐Targeting HIV Vaccines Reach a Turning Point

Rowena A Bull iD, Deborah L Burnett iD

Immunology & Cell Biology · 2026-11 · 104 (10) · 1015-1018

DOI: 10.1111/imcb.70169 ↗

At a glance

Übersichtsarbeit in Immunology & Cell Biology, published online on 2026-10-06. Written by Rowena A Bull and 1 co-authors. Institution: School of Biomedical Sciences, UNSW Sydney, Kensington, New South Wales, Australia. Major MEDLINE topics: AIDS Vaccines, HIV Antibodies, Germ Cells, HIV Infections. 10 references. The full text is freely available (open access, CC BY 4.0). Funded by: UNSW Faculty of Medicine, UNSW Triple I Seed Grant, Hillcrest Foundation and Perpetual Impact.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

This commentary examines three recent Nature studies demonstrating a conceptual shift in HIV vaccine design, demonstrating how germline-targeting HIV vaccines can progress beyond expanding rare broad neutralizing antibody (bnAb) precursors to deliberately guiding their affinity maturation into bnAbs in non-human primates.

Subjects

MeSH terms (MEDLINE)

AIDS VaccinesHIV AntibodiesGerm CellsHIV InfectionsProtein EngineeringAnimalsHumansAntibodies, Neutralizing

Substances

AIDS VaccinesHIV AntibodiesAntibodies, Neutralizing

Authors and institutions

  • School of Biomedical Sciences, UNSW Sydney, Kensington, New South Wales, Australia.
  • The Kirby Institute, UNSW Sydney, Kensington, New South Wales, Australia.
  • Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia.

ORCID profiles: Rowena A Bull, Deborah L Burnett

Funding

  • UNSW Faculty of Medicine
  • UNSW Triple I Seed Grant
  • Hillcrest Foundation and Perpetual Impact
  • Australian National Health and Medical Research Council (NHMRC)
  • National Health and Medical Research Council

Cite

APA

Bull, R. A., & Burnett, D. L. (2026). Engineering Antibody Evolution: Germline‐Targeting HIV Vaccines Reach a Turning Point. Immunology & Cell Biology, 104(10), 1015-1018. https://doi.org/10.1111/imcb.70169

Vancouver

Bull RA, Burnett DL. Engineering Antibody Evolution: Germline‐Targeting HIV Vaccines Reach a Turning Point. Immunology & Cell Biology. 2026;104(10):1015-1018. doi:10.1111/imcb.70169

BibTeX
@article{Bull2026,
  author = {Bull, Rowena A and Burnett, Deborah L},
  title = {Engineering Antibody Evolution: Germline‐Targeting HIV Vaccines Reach a Turning Point},
  journal = {Immunology & Cell Biology},
  year = {2026},
  volume = {104},
  number = {10},
  pages = {1015--1018},
  doi = {10.1111/imcb.70169}
}
Start for free →